Fish oil supplements provide no benefit to brain power

April, 2010

The largest ever trial of fish oil supplements has found no evidence that they offer benefits for cognitive function in older people. However, neither the trial group or the placebo group showed any cognitive decline over the two-year period of the study.

The largest ever trial of fish oil supplements has found no evidence that they offer benefits for cognitive function in older people. The British study enrolled 867 participants aged 70-80 years, and lasted two years. After two years, those receiving fish oil capsules had significantly higher levels of omega-3 fatty acids in their blood than those receiving placebo capsules. However, cognitive function did not decline in either group over the period. The researchers caution that it may be that more time is needed for benefits to show.

http://www.eurekalert.org/pub_releases/2010-04/lsoh-fos042110.php

Reference:

[170] Dangour, A. D., Allen E., Elbourne D., Fasey N., Fletcher A. E., Hardy P., et al.
(2010). Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial.
Am J Clin Nutr. ajcn.2009.29121 - ajcn.2009.29121.

seniors

aging

Lifestyle

Related News

Memory complaints linked to higher risk of MCI & dementia

Data from 6257 older adults (aged 55-90) evaluated from 2005-2012 has revealed that concerns about memory should be taken seriously, with subjective complaints associated with a doubled risk of developing mild cognitive impairment or dementia, and subjective complaints supported by a loved on

New biomarker shows Alzheimer's disease long before symptoms

Analysis of mitochondrial DNA (mtDNA) in the cerebrospinal fluid has found that both symptomatic Alzheimer’s patients and asymptomatic patients at risk of A

Brainwaves indicate the presence and severity of Alzheimer's

Comparison of the EEGs of 27 healthy older adults, 27 individuals with mild Alzheimer's and 22 individuals with moderate cases of Alzheimer’s, has found statistically significant differences across the three groups, using an algorithm that dissects brain waves of varying frequencies.

Distinguishing normal cognitive decline from more serious disorders

Data from two longitudinal studies of older adults (a nationally representative sample of older adults, and the Alzheimer’s Disease Neuroimaging Initiative) has found that a brief cognitive test can distinguish memory decline associated with healthy aging from more serious memory disorders, year

New biomarkers for early Alzheimer's diagnosis

Analysis of 40 spinal marrow samples, 20 of which belonged to Alzheimer’s patients, has identified six

Default mode network changes predict Alzheimer’s

Data from 848 adults of all ages has found that brain volume in the default mode network declined in both healthy and pathological aging, but the greatest decline occurred in Alzheimer’s patients and in those who progressed from mild cognitive impairment to Alzheimer’s disease.

Tracking preclinical Alzheimer's progression

New research supports the classification system for preclinical Alzheimer’s proposed two years ago. The classification system divides preclinical Alzheimer's into three stages:

Tau-amyloid ratio predicts MCI

Initial findings from an analysis of cerebrospinal fluid taken between 1995 and 2005 from 265 middle-aged healthy volunteers, of whom 75% had a close family m

‘Lopsided’ test scores may predict Alzheimer’s sooner

Cognitive testing for dementia has a problem in that low scores on some tests may simply reflect a person's weakness in some cognitive areas, or the presence of a relatively benign form of mild cognitive impairment (one that is not going to progress to dementia).

Predicting if MCI will progress to Alzheimer's

A French study has predicted with 90% accuracy which patients with mild cognitive impairment would receive a clinical diagnosis of Alzheimer's disease within the following two years.

Pages